home / stock / vcnx / vcnx news

VCNX News and Press, Vaccinex Inc. From 03/09/22

Stock Information
Company Name: Vaccinex Inc.
Stock Symbol: VCNX
Market: NASDAQ
Website: vaccinex.com
Menu
VCNX VCNX Quote VCNX Short VCNX News VCNX Articles VCNX Message Board
Get VCNX Alerts

News, Short Squeeze, Breakout and More Instantly...
VCNX - Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta

ROCHESTER, N.Y., March 09, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it has been selected for p...
VCNX - Vaccinex, Inc. to Present at CHDI's 17th Annual HD Therapeutics Conference Meeting

ROCHESTER, N.Y., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that a poster will be presented at...

VCNX - GLSI, VCNX and ACY among mid-day movers

Gainers: Dermata (NASDAQ:DRMA) +25%. IronNet (NYSE:IRNT) +25%. China Online Education (NYSE:COE) +25%. Greenwich LifeSciences (NASDAQ:GLSI) +25%. CleanSpark (NASDAQ:CLSK) +24%. Ebang International Holdings (NASDAQ:EBON) +22%. Lufax Holding (NYSE:LU) +22%. Vaccinex (NASDAQ:VCNX) +21%. The Vale...

VCNX - BioCardia, Biophytis top healthcare gainers; Kiromic, Mainz Biomed among losers

Gainers: BioCardia BCDA +32%. Biophytis BPTS +17%. Mersana Therapeutics MRSN +7%. Liquidia (NASDAQ:LQDA) +5%. Vaccitech (NASDAQ:VACC) +3%. Losers: Kiromic BioPharma KRBP -17%. Mainz Biomed (NASDAQ:MYNZ) -9%. Vaccinex (NASDAQ:VCNX) -7%. NeuroBo Phar...
VCNX - 5 Penny Stocks To Buy Now According To Insiders In 2022

Want to find the best penny stocks to buy right now? I bet you’ve got a strategy in mind. Are you hunting for chart set-ups or searching for unusual volume? Maybe you’ve got a price range in mind, like penny stocks under $1 . On the other hand, you might be looking...

VCNX - Vaccinex Announces $6.6 Million Private Placement

Participants include a syndicate of existing and new shareholders Contributes to total of $10.1 million in new equity financing for January, 2022 ROCHESTER, N.Y., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pione...

VCNX - R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments

Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of deaths in...
VCNX - 4 Hot Penny Stocks To Buy Under $5 Right Now

4 Penny Stocks To Watch Premarket In The Stock Market Today Penny stocks and risk go hand-in-hand. But with that higher risk comes the potential for higher rewards as well. Two of the biggest things to factor in are research and time. Before jumping into any trade, understanding why cer...

VCNX - Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer

ROCHESTER, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today repor...

VCNX - Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis

Phase 1b segment evaluated safety and tolerability of the combination Paves the way to expand and accelerate enrollment in the Phase 2 segment of the study ROCHESTER, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-s...
Previous 10 Next 10